COMMITED TO CBD & PSILOCYBIN SCIENCE!
The Company is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies.
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands. In addition, its new established division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan will enter the international growing cannabis and psilocybin market for medical applications such as cancer, mental disorders, chronic pain, and others is expected to propel revenue growth in Canada, the United States, South Africa and Europe.
From Seed to Store, a new efficient way to operate a company; from the cultivation, the processing, the manufacturing, the labeling, to the distribution in store – a chain of operation that enables us to maximize our profit, but also to be very competitive, and therefore guarantee an excellent product and service to our consumers.”
Learn more at https://wuhn.org/